Research Topics
Genomes and Genes | C FestucciaSummaryAffiliation: University of L'Aquila Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Culture conditions modulate cell phenotype and cause selection of subpopulations in PC3 prostate cancer cell lineC Festuccia
Department of Experimental Medicine, Medical School, University of L Aquila, 67100 L Aquila, Italy
Anticancer Res 20:4367-71. 2000..However, this heterogeneity may represent a good model in the study of tumor progression...- Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cellsAdriano Angelucci
Department of Experimental Medicine, University of L Aquila, Medical School, Coppito 2, L Aquila, Italy
Prostate 59:157-66. 2004..The aim of this study was to elucidate some mechanisms by which stroma controls tumor progression... - Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitorsClaudio Festuccia
Departments of Experimental Medicine, University of L Aquila, L Aquila, Italy
Prostate 68:965-74. 2008..PTEN is a well-characterized tumor suppressor that negatively regulates cell growth and survival through the modulation of PI3K/Akt pathway... - Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cellsClaudio Festuccia
Prostate Biology Laboratory Department of Experimental Medicine, University of L Aquila Science and Technology School, Via Vetoio Coppito 2, 67100 L Aquila, Italy
J Cancer Res Clin Oncol 131:243-54. 2005.... - Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patientsClaudio Festuccia
Department of Experimental Medicine, University of L Aquila, 67100 L Aquila, Italy
Oncol Rep 18:1321-7. 2007.... - Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitroClaudio Festuccia
Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
Int J Cancer 115:630-40. 2005..This causes a significant delay in the onset of EGFR-driven androgen independence... - Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samplesClaudio Festuccia
Department of Experimental Medicine, University of L Aquila Medical School, 67100 L Aquila, Italy
Int J Oncol 26:1353-62. 2005..The primary cultures derived from prostatic tissues can be an extremely important method to study genetic and molecular changes involved in PCa progression... - Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell disseminationClaudio Festuccia
Department of Experimental Medicine, L Aquila, Italy
Thromb Haemost 93:964-75. 2005.... - Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell linesC Festuccia
Department of Experimental Medicine, University of L Aquilla, Italy
Endocr Relat Cancer 12:983-98. 2005.... - Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cellsClaudio Festuccia
Department of Experimental Medicine, University of L Aquila, 67100 L Aquila, Italy
Oncol Rep 18:503-11. 2007..Therefore, the ability of tumor cells to maintain high ERK activity under EGFR inhibition could represent a potential mechanism of the resistance to gefitinib... - In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinomaClaudio Festuccia
Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
Prostate 67:1255-64. 2007..Neurotrophine tyrosine kinase receptors (NTR) are expressed in prostate carcinoma (PCa), and their distribution seems to be related to disease malignancy... - Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitroClaudio Festuccia
Department of Experimental Medicine, University of L Aquila, I 67100 L Aquila, Italy
Int J Oncol 30:193-200. 2007..CEP-701 is a trademark of Cephalon Inc., West Chester, PA, USA... - Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cellsClaudio Festuccia
Department of Experimental Medicine, University of L Aquila, I 67100 L Aquila, Italy
Int J Oncol 33:381-8. 2008.... - Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cellsC Festuccia
Department of Experimental Medicine, Medical School, University of L Aquila, Italy
Int J Cancer 85:407-15. 2000.... - Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix componentsC Festuccia
Department of Experimental Medicine, Medical School, University of L Aquila, Italy
Int J Cancer 81:395-403. 1999..Given the widespread tissue distribution of TGF-beta1, and the high levels present in the bone, this cytokine may be an important autocrine-paracrine modulator of the bone invasive phenotype in vivo... - Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatmentClaudio Festuccia
Department of Experimental Medicine, Chair of General Pathology, University of L Aquila, Italy
Prostate 69:337-45. 2009..It has been demonstrated that the simultaneous high expression of p185(HER2) and TrkA might confer a proliferative advantage to PCa cells... - Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires beta1 integrin engagementClaudio Festuccia
Department of Experimental Medicine, University of L Aquila, Italy
Exp Cell Res 280:1-11. 2002..This finding supports the idea that cellular responses to growth factors may be driven by cell-matrix interactions and stresses the role of neuroendocrine factors in prostate carcinoma progression... - Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer modelsClaudio Festuccia
Department of Experimental Medicine, Chair of General Pathology, University of L Aquila, 67100 L Aquila, Italy
Endocr Relat Cancer 16:401-13. 2009..Our results provide a rationale for clinical trials on combination treatments with azacitidine in patients with hormone-refractory and chemoresistant prostate tumors... - Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancerClaudio Festuccia
Department of Experimental Medicine, University of L Aquila, 67100 L Aquila, Italy
Endocr Relat Cancer 14:601-11. 2007.... - Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasionC Festuccia
Department of Experimental Medicine, Medical School, University of L Aquila, Italy
Oncol Res 11:17-31. 1999.... - Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cellsGiovanni Luca Gravina
Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
Prostate 68:793-801. 2008..We also studied whether epigenetically reactivated AR is a target for bicalutamide therapy... - Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levelsGiovanni Luca Gravina
Department of Experimental Medicine, University of L Aquila, San Salvatore Hospital, Italy
Urology 74:452-7. 2009..To evaluate the role of Her2/neu as a molecular marker predictive of the treatment response to bicalutamide in prostate cancer (PCa)... - Biomolecular characterization of human glioblastoma cells in primary cultures: differentiating and antiangiogenic effects of natural and synthetic PPARgamma agonistsE Benedetti
Department of Basic and Applied Biology, University of L Aquila, L Aquila, Italy
J Cell Physiol 217:93-102. 2008..We provide evidence that PPARgamma agonists may interfere with glioblastoma growth and malignancy and might be taken in account as novel antitumoral drugs... - 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumorsGiovanni Luca Gravina
Division of Radiotherapy, Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
Prostate 70:1166-78. 2010..This study tested the hypothesis that 5-Aza may restore and enhance the responsiveness of HRPC cells to anti-hormonal therapy on Androgen receptor (AR) expressing (22rv1) and AR-deficient (PC3) cells... - Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitroI Recchia
Department of Experimental Medicine, Via Vetoio, Coppito 2, 67100 L'Aquila, Italy
Eur J Cancer 39:1927-35. 2003..Collectively, these data demonstrate that the pyrrolopyrimidine-derived c-Src inhibitors significantly reduced PC3 cell activities associated with their malignant phenotype... - Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude miceAdriano Angelucci
Department of Surgery, University of L Aquila Via Vetoio, Coppito 2, 67100 L Aquila, Italy
Endocr Relat Cancer 13:197-210. 2006..In conclusion, our data suggest that the use of gefitinib as a therapeutic agent may be indicated in the control of PCa spreading to bone... - Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary culturesCarlo Vicentini
Prostate Biology Laboratory, Department of Surgery, University of L'Aquila, Medical School, Coppito-2, 67100, L'Aquila, Italy
J Cancer Res Clin Oncol 129:165-74. 2003..CONCLUSION. Our experiments suggest that EGFR-TKIs such as ZD1839 may have potential in blocking the growth and progression of human prostatic cancers even in early phases of the disease... - Establishment and characterization of a human prostatic carcinoma cell strain obtained from exfoliated tumor cells after prostatic massageM Bologna
Department of Experimental Medicine, University of L'Aquila Medical School, Italy
Tumori 77:70-5. 1991.... - Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancerGiovanni Luca Gravina
Department of Urology, University of L Aquila, Italy
Urology 70:728-33. 2007.... - Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cellsDanilo Millimaggi
Department of Experimental Medicine, University of L'Aquila, 67100 L'Aquila, Italy
Int J Oncol 28:909-14. 2006..Collectively, these findings indicate that osteoblasts produce factor/s able to modify the invasive capability of prostate cancer cells, increasing the amount of shed vesicles and of their associated lytic enzymes... - PPARbeta agonists trigger neuronal differentiation in the human neuroblastoma cell line SH-SY5YS Di Loreto
ITOI, CNR, L Aquila, Italy
J Cell Physiol 211:837-47. 2007.... - The impact of conventional or hypofractionated radiotherapy on voice quality and oncological outcome in patients with early glottic cancerL Di Nicola
Department of Experimental Medicine, Division of Radiotherapy, Radiobiology Laboratory, University of L Aquila, L Aquila, Italy
Oncol Rep 24:1383-8. 2010..Thus, we provide clinical evidence to justify trends already emerging toward hypofractionated regimens in early glottic cancer... - Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activatorsAdriano Angelucci
Department of Experimental Medicine, University of L Aquila, Italy
Biol Chem 383:229-34. 2002..Our findings suggest that osteopontin may confer selective malignant potential to prostate cancer cells through the enhancement of their invasive and proteolytic capability... - Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancerV Tombolini
Department of Experimental Medicine, Division of Radiotherapy, University of L Aquila, L Aquila, Italy
Prostate Cancer Prostatic Dis 13:34-8. 2010..Our study seems to suggest that our hypofractionated radiotherapy schedule for the treatment of prostate cancer is safe in terms of late urinary morbidity. Further study will be required to confirm our results... - Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386Claudio Festuccia
Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
J Urol 180:367-72. 2008.... - Evaluation of metastatic potential in prostate carcinoma: an in vivo modelAdriano Angelucci
Department of Basic and Applied Biology, University of L Aquila, Medical School and Science and Technology School, Coppito 2, I 67100 L Aquila, Italy
Int J Oncol 25:1713-20. 2004..This study demonstrates that heart injection of prostate cancer cells in nude mice may represent a good experimental model to investigate the pathophysiology of bone and bone marrow metastases in vivo... - Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell lineV Dolo
Dipartimento di Medicina Sperimentale, Universita di L Aquila, Italy
Oncol Res 9:129-38. 1997.... - Female reproductive dysfunction during ageing: role of methylglyoxal in the formation of advanced glycation endproducts in ovaries of reproductively-aged miceC Tatone
Department of Health Sciences, University of L Aquila, Via Vetoio, L Aquila, Italy
J Biol Regul Homeost Agents 24:63-72. 2010..In conclusion, the present results show that impaired MG detoxification causing relevant damage to the ovarian proteome might be one of the mechanisms underlying reproductive ageing and/or ageing-like ovarian diseases... - Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitroV Dolo
Dipartimento di Medicina Sperimentale, Universita dell Aquila, Italy
Clin Exp Metastasis 17:131-40. 1999..Taken together, our results point to a possible role of shed vesicles, both in vivo and in vitro, in proteolysis that mediates invasion and spread of ovarian epithelial carcinoma cells... - Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancerGiovanni Luca Gravina
Department of Experimental Medicine, Division of Radiotherapy, University of L Aquila, 67100 L Aquila, Italy
Int J Oncol 35:1133-9. 2009.... - Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitroClaudio Festuccia
Laboratory of Radiobiology, Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
Prostate 69:1529-37. 2009..Why, differently to other tumors, have EGFR inhibitors been so ineffective in human prostate cancer? This is the question that we have set in this report... - Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptorsClaudio Festuccia
Radiobiology Laboratory, Department of Experimental Medicine, University of L Aquila, L Aquila, Italy
Prostate 70:1340-9. 2010..This study explored the in vitro effects on DU145 and PC3 cell lines, two models of androgen-independent prostate cancer, of a fourth generation GnRH antagonist (Ozarelix)... - Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cellsAdriano Angelucci
Dip Scienze Chirurgiche, University of L Aquila, 67100 L Aquila, Italy
Eur J Cancer 42:2838-45. 2006..Our data suggest a promising role for pyrazolo[3,4-d]pyrimidines c-Src inhibitors in the control of a highly invasive tumour phenotype... - PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF)Annamaria Cimini
Department of Basic and Applied Biology, University of L Aquila, L Aquila, Italy
Int J Cancer 117:923-33. 2005..Moreover, the gamma-agonist, once experimented and validated on man, may represent a useful coadjuvant in glioblastoma therapy and in the prevention of recurrences... - Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancerPierluigi Bonfili
Department of Experimental Medicine, Division of Radiation Oncology, S Salvatore Hospital, L Aquila, University of L Aquila, Medical School, Medical School Via Vetoio, Coppito 11 A, 67100 L Aquila, Italy
Lung Cancer 67:81-5. 2010..Although the performances of our regimen were lower than the ones achieved by SBRT, our therapeutic option may offer a lower incidence of complications against a satisfactory local tumor control... - Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary culturesCarlo Vicentini
Chair of Urology, Department of Surgery, University of L'Aquila Medical School, Via Vetoio, Coppito-2, 67100 L'Aquila, Italy
Anticancer Res 22:2917-22. 2002..However, its efficacy in AR-negative cells requires further research... - Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cellsGiovanni Luca Gravina
Division of Urology, Department of Surgery, University of L'Aquila, L'Aquila, Italy
Int J Oncol 25:97-104. 2004..Up-regulation of EGFR in response to long-term HF treatment could represent an attempt to rescue cell growth through a compensatory survival pathway... - Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptorEugenia Scaccianoce
Centre for Endocrinological Oncology, Institute of Endocrinology, University of Milan, Italy
Oncol Res 14:101-12. 2003..Some of the effects described may thus be mediated by a ligand-independent activation of AR in DU145 cells... - Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasiaCarlo Vicentini
Department of Surgery, University of L'Aquila, Italy
J Cancer Res Clin Oncol 130:217-21. 2004..One of the clinical benefits resulting from the use of this new assay would be to refine the biopsy indication and to avoid for several patients without Pca the unnecessary cost and the complications of prostate biopsy... - Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2Federica Casilli
, L'Aquila, Italy
Biochem Pharmacol 69:385-94. 2005..These data suggest that repertaxin is a potent and specific inhibitor of a wide range of CXCL8-mediated activities related to leukocyte recruitment and functional activation in inflammatory sites...